

Lena Åredal Assumes Role as CEO of SyntheticMR AB (publ)

On June 13, the Board of Directors of SyntheticMR announced the appointment of Lena Åredal as the company's new Chief Executive Officer, with a start date no later than mid-December. Today, Lena officially assumes the role as CEO, succeeding Acting CEO Johanna Norén, who returns to her position as CFO.

Prior to taking office, Lena Åredal acquired 139,470 shares in SyntheticMR AB.

For further information, please contact:

Gisli Hennermark, Chairman of the board, phone: +46 70-420 83 00

Lena Åredal, CEO, phone: +46 76-770 99 08

Linköping, September 1st, 2025

.

SyntheticMR AB (publ) develops and markets innovative imaging solutions that enhance neuroimaging workflow efficiency and diagnostic precision. SyntheticMR's SyMRI® solution measures brain absolute tissue properties and generates multiple contrast-weighted images, performs automatic segmentation of biomarkers, and delivers quantitative data in a single fast scan. Combinostics, a SyntheticMR company, offers the Al-powered cNeuro® suite of products that help clinicians make a difference in the lives of patients with neurological disorders. Our products are, among other things, CE-marked and FDA-approved, and we are listed on Spotlight Stock Market Exchange in Stockholm. SyntheticMR is headquartered in Linköping, Sweden, with an additional office in Tampere, Finland. For more information, please visit syntheticmr.com and combinostics.com.